PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-314.19%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
7.75%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
-313.81%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-286.19%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-286.19%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
6.89%
Share reduction more than 1.5x GNPX's 80.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
6.89%
Diluted share reduction more than 1.5x GNPX's 80.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
17.02%
OCF growth above 1.5x GNPX's 7.14%. David Dodd would confirm a clear edge in underlying cash generation.
16.84%
FCF growth above 1.5x GNPX's 7.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14746.74%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19558.18%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-11613.56%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-30946.59%
Negative 10Y net income/share CAGR while GNPX is at 99.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-34054.52%
Negative 5Y net income/share CAGR while GNPX is 96.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-30407.41%
Negative 3Y CAGR while GNPX is 96.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-3646.86%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-832.34%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-628.80%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-341.43%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
43.14%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.